Tools
Tools
Wedge, David C., Gundem, Gunes, Mitchell, Thomas, Woodcock, Dan J., Martincorena, Inigo, Ghori, Mohammed, Zamora, Jorge, Butler, Adam, Whitaker, Hayley, Kote-Jarai, Zsofia, Alexandrov, Ludmil B., Van Loo, Peter, Massie, Charlie E., Dentro, Stefan, Warren, Anne Y., Verrill, Clare, Berney, Dan M., Dennis, Nening, Merson, Sue, Hawkins, Steve, Howat, William, Lu, Yong-Jie, Lambert, Adam, Kay, Jonathan, Kremeyer, Barbara, Karaszi, Katalin, Luxton, Hayley, Camacho, Niedzica, Marsden, Luke, Edwards, Sandra, Matthews, Lucy, Bo, Valeria, Leongamornlert, Daniel, McLaren, Stuart, Ng, Anthony, Yu, Yongwei, Zhang, Hongwei, Dadaev, Tokhir, Thomas, Sarah, Easton, Douglas F., Ahmed, Mahbubl, Bancroft, Elizabeth, Fisher, Cyril, Livni, Naomi, Nicol, David, Tavaré, Simon, Gill, Pelvender, Greenman, Christopher, Khoo, Vincent, Van As, Nicholas, Kumar, Pardeep, Ogden, Christopher, Cahill, Declan, Thompson, Alan, Mayer, Erik, Rowe, Edward, Dudderidge, Tim, Gnanapragasam, Vincent, Shah, Nimish C., Raine, Keiran, Jones, David, Menzies, Andrew, Stebbings, Lucy, Teague, Jon, Hazell, Steven, Corbishley, Cathy, de Bono, Johann, Attard, Gerhardt, Isaacs, William, Visakorpi, Tapio, Fraser, Michael, Boutros, Paul C., Bristow, Robert G., Workman, Paul, Sander, Chris, Hamdy, Freddie C., Futreal, Andrew, McDermott, Ultan, Al-Lazikani, Bissan, Lynch, Andrew G., Bova, G. Steven, Foster, Christopher S., Brewer, Daniel S. 
ORCID: https://orcid.org/0000-0003-4753-9794, Neal, David E., Cooper, Colin S. ORCID: https://orcid.org/0000-0003-2013-8042 and Eeles, Rosalind A.
(2018)
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
Nature Genetics, 50.
682–692.
ISSN 1061-4036
Preview |
PDF (Accepted manuscript)
- Accepted Version
Download (2MB) | Preview |
Abstract
Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for NEAT1 and FOXA1 acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion-negative cancers. Computational chemogenomic (canSAR) analysis of prostate cancer mutations identified 11 targets of approved drugs, 7 targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Science > School of Computing Sciences Faculty of Medicine and Health Sciences > Norwich Medical School Faculty of Science > School of Biological Sciences Faculty of Science > School of Natural Sciences |
| UEA Research Groups: | Faculty of Science > Research Groups > Computational Biology Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | Pure Connector |
| Date Deposited: | 16 Jan 2018 10:30 |
| Last Modified: | 19 Oct 2023 02:07 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/65943 |
| DOI: | 10.1038/s41588-018-0086-z |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |